MA42700B1 - Dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate - Google Patents
Dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamateInfo
- Publication number
- MA42700B1 MA42700B1 MA42700A MA42700A MA42700B1 MA 42700 B1 MA42700 B1 MA 42700B1 MA 42700 A MA42700 A MA 42700A MA 42700 A MA42700 A MA 42700A MA 42700 B1 MA42700 B1 MA 42700B1
- Authority
- MA
- Morocco
- Prior art keywords
- metabotropic glutamate
- glutamate receptors
- allosteric modulator
- oxime derivative
- chromone
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 229940125516 allosteric modulator Drugs 0.000 title 1
- IPDGWIYTNQXKSP-UHFFFAOYSA-N n-chromen-4-ylidenehydroxylamine Chemical class C1=CC=C2C(=NO)C=COC2=C1 IPDGWIYTNQXKSP-UHFFFAOYSA-N 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 2
- 229960004502 levodopa Drugs 0.000 abstract 2
- -1 oxime chromone derivative Chemical class 0.000 abstract 2
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000003257 excitatory amino acid Substances 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne un dérivé de chromone oxime de formule (i), qui est un modulateur des récepteurs du système nerveux sensible au glutamate acide aminé neuro-excitateur et qui présente une exposition au cerveau avantageusement élevée à l'issue de l'administration par voie buccale, pour le traitement ou la prévention de la dyskinésie induite par la lévodopa. La présente invention décrit également une thérapie améliorée de la maladie de parkinson, en utilisant le dérivé de chromone oxime de formule (i) en combinaison avec la lévodopa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/069601 WO2016030444A1 (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropes au glutamate |
| EP15188368 | 2015-10-05 | ||
| PCT/EP2016/070175 WO2017032874A1 (fr) | 2015-08-27 | 2016-08-26 | Dérivé de chromone oxime pénétrant le cerveau pour la thérapie de la dyskinésie induite par la lévodopa |
| EP16769872.9A EP3341380B1 (fr) | 2015-08-27 | 2016-08-26 | Dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42700B1 true MA42700B1 (fr) | 2019-12-31 |
Family
ID=54260666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42700A MA42700B1 (fr) | 2015-08-27 | 2016-08-26 | Dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10532057B2 (fr) |
| EP (2) | EP3341380B1 (fr) |
| JP (1) | JP2018528205A (fr) |
| KR (1) | KR20180041234A (fr) |
| CN (1) | CN108349993A (fr) |
| AU (1) | AU2016313138A1 (fr) |
| CA (1) | CA2995313A1 (fr) |
| CL (1) | CL2018000497A1 (fr) |
| CY (1) | CY1122401T1 (fr) |
| DK (1) | DK3341380T3 (fr) |
| DO (1) | DOP2018000060A (fr) |
| EA (1) | EA035016B1 (fr) |
| ES (1) | ES2764490T3 (fr) |
| HR (1) | HRP20192250T1 (fr) |
| HU (1) | HUE047531T2 (fr) |
| IL (1) | IL257655A (fr) |
| LT (1) | LT3341380T (fr) |
| MA (1) | MA42700B1 (fr) |
| ME (1) | ME03591B (fr) |
| MX (1) | MX2018002255A (fr) |
| NI (1) | NI201800031A (fr) |
| PH (1) | PH12018500430A1 (fr) |
| PL (1) | PL3341380T3 (fr) |
| PT (1) | PT3341380T (fr) |
| RS (1) | RS59651B1 (fr) |
| RU (1) | RU2018110580A (fr) |
| SI (1) | SI3341380T1 (fr) |
| SM (1) | SMT201900720T1 (fr) |
| TN (1) | TN2018000061A1 (fr) |
| WO (1) | WO2017032874A1 (fr) |
| ZA (1) | ZA201801642B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3186257B1 (fr) * | 2014-08-27 | 2019-02-06 | Prexton Therapeutics SA | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| PT3341380T (pt) | 2015-08-27 | 2019-12-19 | Prexton Therapeutics Sa | Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa |
| KR20210039368A (ko) | 2018-07-26 | 2021-04-09 | 도메인 테라퓨틱스 | 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도 |
| EP3807077A4 (fr) | 2018-12-14 | 2021-12-29 | Hewlett-Packard Development Company, L.P. | Évaluation de volumes de construction virtuels candidats |
| GB202016425D0 (en) * | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| CN115594655B (zh) * | 2022-09-16 | 2023-08-15 | 桂林医学院 | 色酮肟类衍生物及其制备方法和应用 |
| KR102903389B1 (ko) * | 2022-11-30 | 2025-12-23 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| JP3993651B2 (ja) | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (fr) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Procédé pour la préparation de dérivés the Benzopyran substitués en position 4 |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US20070027216A1 (en) | 2005-07-15 | 2007-02-01 | Bridget Larson | Novel hydrochloride salts of levodopa |
| JP2010533147A (ja) | 2007-07-13 | 2010-10-21 | アデックス ファルマ エス．エイ． | 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体 |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| EP2493871B1 (fr) | 2009-10-30 | 2014-09-03 | Domain Therapeutics | Nouveaux dérivés d'oxime et leur utilisation en tant que modulateurs allostériques de récepteurs du glutamate métabotropique |
| SG10201510665WA (en) | 2009-12-04 | 2016-01-28 | Sunovion Pharmaceuticals Inc | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
| EA026419B1 (ru) * | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона |
| EP3186257B1 (fr) * | 2014-08-27 | 2019-02-06 | Prexton Therapeutics SA | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| PT3341380T (pt) | 2015-08-27 | 2019-12-19 | Prexton Therapeutics Sa | Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa |
-
2016
- 2016-08-26 PT PT167698729T patent/PT3341380T/pt unknown
- 2016-08-26 AU AU2016313138A patent/AU2016313138A1/en not_active Abandoned
- 2016-08-26 CN CN201680062784.8A patent/CN108349993A/zh active Pending
- 2016-08-26 HU HUE16769872A patent/HUE047531T2/hu unknown
- 2016-08-26 LT LTEP16769872.9T patent/LT3341380T/lt unknown
- 2016-08-26 US US15/755,435 patent/US10532057B2/en not_active Expired - Fee Related
- 2016-08-26 WO PCT/EP2016/070175 patent/WO2017032874A1/fr not_active Ceased
- 2016-08-26 ES ES16769872T patent/ES2764490T3/es active Active
- 2016-08-26 EP EP16769872.9A patent/EP3341380B1/fr active Active
- 2016-08-26 HR HRP20192250TT patent/HRP20192250T1/hr unknown
- 2016-08-26 RS RS20191571A patent/RS59651B1/sr unknown
- 2016-08-26 DK DK16769872.9T patent/DK3341380T3/da active
- 2016-08-26 EA EA201890590A patent/EA035016B1/ru not_active IP Right Cessation
- 2016-08-26 CA CA2995313A patent/CA2995313A1/fr not_active Abandoned
- 2016-08-26 MA MA42700A patent/MA42700B1/fr unknown
- 2016-08-26 SI SI201630559T patent/SI3341380T1/sl unknown
- 2016-08-26 PL PL16769872T patent/PL3341380T3/pl unknown
- 2016-08-26 EP EP19207959.8A patent/EP3696182A1/fr not_active Withdrawn
- 2016-08-26 KR KR1020187008542A patent/KR20180041234A/ko not_active Withdrawn
- 2016-08-26 JP JP2018510876A patent/JP2018528205A/ja active Pending
- 2016-08-26 TN TNP/2018/000061A patent/TN2018000061A1/en unknown
- 2016-08-26 SM SM20190720T patent/SMT201900720T1/it unknown
- 2016-08-26 RU RU2018110580A patent/RU2018110580A/ru not_active Application Discontinuation
- 2016-08-26 ME MEP-2019-346A patent/ME03591B/fr unknown
- 2016-08-26 MX MX2018002255A patent/MX2018002255A/es unknown
-
2018
- 2018-02-21 IL IL257655A patent/IL257655A/en unknown
- 2018-02-23 CL CL2018000497A patent/CL2018000497A1/es unknown
- 2018-02-23 NI NI201800031A patent/NI201800031A/es unknown
- 2018-02-26 DO DO2018000060A patent/DOP2018000060A/es unknown
- 2018-02-27 PH PH12018500430A patent/PH12018500430A1/en unknown
- 2018-03-09 ZA ZA2018/01642A patent/ZA201801642B/en unknown
-
2019
- 2019-12-10 CY CY20191101297T patent/CY1122401T1/el unknown
- 2019-12-11 US US16/709,988 patent/US20200171042A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42700B1 (fr) | Dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate | |
| JOP20200114B1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| EA201991316A1 (ru) | Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту | |
| FR3065642B1 (fr) | Utilisation de 20-hydroxyecdysone et ses derives dans le traitement des myopathies | |
| JOP20190193A1 (ar) | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان | |
| FR3084254B1 (fr) | Derives deuteres du lanifibranor | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA38959A1 (fr) | Modulateurs du facteur b du complément | |
| MA35857B1 (fr) | Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k | |
| EA201890767A1 (ru) | C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений | |
| MA46490A1 (fr) | Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués | |
| EA201892153A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
| EA201992354A1 (ru) | Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона | |
| FR3061856B1 (fr) | Utilisations therapeutiques d'une poudre d'insectes | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| EA202090116A1 (ru) | Композиции, содержащие конъюгаты каннабиноидного аналога, и способы применения | |
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| EA202191684A1 (ru) | Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии | |
| EA202192199A1 (ru) | Композиции, содержащие коричную кислоту, и способы их применения | |
| SA522432749B1 (ar) | I/alk5 مشتقات بنزيلاميد كمستقبل لمثبطات عامل النمو المتحول-بيتا | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения |